Table 3 Estimated relative risk (odds ratio) of exhibiting metabolic syndrome components associated with the SST poly-T repeat polymorphism genotype

Entire sample^a

13/13

p=

OR

1

1

1

1

1

1

13/14

OR

1.46

1.24

0.96

0.66

1.68

1.10

p-value

95%CI

0.18

(0.84–2.53)

0.39

(0.76–2.04)

0.87

(0.59–1.57)

0.18

(0.36–1.21)

0.05

(1.01–2.81)

0.71

(0.66–1.83)

13/15

OR

1.07

1.24

1.02

1.26

1.07

1.13

p-value

95%CI

0.57

(0.85–1.34)

0.05

(1.01–1.53)

0.85

(0.83–1.26)

0.05

(1.00–1.59)

0.53

(0.86–1.34)

0.28

(0.91–1.40)

13/16

OR

1.60

1.55

1.55

1.48

1.43

1.79

p-value

95%CI

0.01

(1.10–2.33)

0.01

(1.11–2.17)

0.01

(1.11–2.17)

0.03

(1.04–2.11)

0.04

(1.02–2.02)

<  0.01

(1.27–2.53)

Men^b

13/13

OR

1

1

1

1

1

1

13/14

OR

0.99

1.49

0.79

0.55

1.71

0.85

p-value

95%CI

0.98

(0.46–2.12)

0.25

(0.75–2.96)

0.50

(0.41–1.54)

0.15

(0.24–1.25)

0.12

(0.87–3.37)

0.64

(0.66–1.83)

13/15

OR

0.91

1.32

1.03

1.09

0.99

1.00

p-value

95%CI

0.58

(0.65–1.27)

0.07

(0.98–1.78)

0.84

(0.77–1.39)

0.59

(0.79–1.50)

0.96

(0.73–1.34)

1.00

(0.91–1.40)

13/16

OR

1.43

1.93

1.68

1.08

1.26

1.50

p-value

95%CI

0.20

(0.83–2.47)

0.01

(1.22–3.07)

0.03

(1.06–2.65)

0.75

(0.68–1.72)

0.31

(0.81–1.96)

0.08

(0.95–2.37)

Women^b

13/13

OR

1

1

1

1

1

1

13/14

OR

2.08

1.04

1.21

0.86

1.66

1.59

p-value

95%CI

0.06

(0.98–4.42)

0.91

(0.49–2.21)

0.61

(0.58–2.52)

0.74

(0.35–2.11)

0.21

(0.75–3.67)

0.24

(0.74–3.43)

13/15

OR

1.22

1.12

1.01

1.45

1.17

1.26

p-value

95%CI

0.21

(0.89–1.66)

0.49

(0.82–1.52)

0.94

(0.75–1.37)

0.03

(1.03–2.04)

0.35

(0.84–1.64)

0.16

(0.91–1.73)

13/16

OR

1.77

1.19

1.41

2.33

1.73

2.25

p-value

95%CI

0.03

(1.06–2.95)

0.51

(0.72–1.98)

0.18

(0.86–2.32)

<  0.01

(1.33–4.09)

0.04

(1.02–2.93)

< 0.01

(1.33–3.79)